Outcomes at 7 years post‐transplant in black vs nonblack kidney transplant recipients administered belatacept or cyclosporine in<scp>BENEFIT</scp>and<scp>BENEFIT</scp>‐<scp>EXT</scp>
Sander Florman(Mount Sinai Hospital), Christian P. Larsen(Emory University Hospital), Valter Duro Garcı́a(Hospital São Vicente), Martin S. Polinsky(Bristol-Myers Squibb (United States)), Flavio Vincenti(University of California, San Francisco), Kim Rice(Baylor University Medical Center), Antoine Dürrbach(Inserm), Barbara A. Bresnahan(Medical College of Wisconsin), Carlos Zayas(Unknown), Ulf Meier‐Kriesche(Bristol-Myers Squibb (United States)), José Medina‐Pestana(Hospital do Rim e Hipertensão), Lionel Rostaing(Centre Hospitalier Universitaire de Grenoble), Marwan Abouljoud(Henry Ford Hospital), Kellie Calderon(Bristol-Myers Squibb (United States)), Laura Mulloy(Augusta University), Lingfeng Yang(Bristol-Myers Squibb (United States))
Cited by 9
Related Papers
Rational Development of LEA29Y (belatacept), a High-Affinity Variant of CTLA4-Ig with Potent Immunosuppressive Properties
|American Journal of Transplantation|2005|708
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma
|Transplantation|2015|417
Assessment of Cytomegalovirus-Specific Cell-Mediated Immunity for the Prediction of Cytomegalovirus Disease in High-Risk Solid-Organ Transplant Recipients: A Multicenter Cohort Study
|Clinical Infectious Diseases|2012|299
Cytomegalovirus in transplantation – challenging the<i>status quo</i>
|Clinical Transplantation|2006|288